Abstract
m-Chlorophenylpiperazine (m-CPP), a 5-HTergic agonist, is a well known migrainous headache provoking agent, probably mediated by NO release. In this study m-CPP was given to 97 subjects, including cluster headache (CH) and migraine patients, to test the hypothesis of an altered 5-HT activity/sensitivity in these pathologies. Sixty-one episodic CH patients, 44 in cluster period and 17 in remission, 10 migraine without aura sufferers, 7 low back pain (LBP) patients and 19 healthy subjects were investigated. A single oral dose of m-CPP, 0.5 mg/Kg, was given. m-CPP plasma levels were not significantly different between the 5 groups. Migrainous headache was reported by 2 healthy subjects (10.5%), 3 cluster period CH patients (6.8%), 2 CH patients in remission (11.7%), 2 migraineurs (20%) and 1 LBP patient (14.2%). Eighteen cluster period CH patients (41%) had a CH attack outside the typical hour of appearance, 2 ±0.2 hours (mean ±sem) after m-CPP administration. This study suggests that 5-HTergic stimulation, in particular of 5-HT2 C/B receptors, play a key role both in migraine and, above all, in cluster headache mechanisms. Nitric oxide release probably is the common factor inducing head pain in both the headache forms.
| Original language | English |
|---|---|
| Pages (from-to) | 45 |
| Number of pages | 1 |
| Journal | Italian Journal of Neurological Sciences |
| Volume | 18 |
| Issue number | 4 |
| Publication status | Published - 1997 |
Fingerprint
ASJC Scopus subject areas
- Neuroscience(all)
- Clinical Neurology
Cite this
Head pain mechanisms and serotonin in human : A study on m-chlorophenylpiperazine-induced headache and possible no involvement. / Leone, M.; Attanasio, A.; D'Amico, D.; Grazzi, L.; Moschiano, F.; Bussone, G.
In: Italian Journal of Neurological Sciences, Vol. 18, No. 4, 1997, p. 45.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Head pain mechanisms and serotonin in human
T2 - A study on m-chlorophenylpiperazine-induced headache and possible no involvement
AU - Leone, M.
AU - Attanasio, A.
AU - D'Amico, D.
AU - Grazzi, L.
AU - Moschiano, F.
AU - Bussone, G.
PY - 1997
Y1 - 1997
N2 - m-Chlorophenylpiperazine (m-CPP), a 5-HTergic agonist, is a well known migrainous headache provoking agent, probably mediated by NO release. In this study m-CPP was given to 97 subjects, including cluster headache (CH) and migraine patients, to test the hypothesis of an altered 5-HT activity/sensitivity in these pathologies. Sixty-one episodic CH patients, 44 in cluster period and 17 in remission, 10 migraine without aura sufferers, 7 low back pain (LBP) patients and 19 healthy subjects were investigated. A single oral dose of m-CPP, 0.5 mg/Kg, was given. m-CPP plasma levels were not significantly different between the 5 groups. Migrainous headache was reported by 2 healthy subjects (10.5%), 3 cluster period CH patients (6.8%), 2 CH patients in remission (11.7%), 2 migraineurs (20%) and 1 LBP patient (14.2%). Eighteen cluster period CH patients (41%) had a CH attack outside the typical hour of appearance, 2 ±0.2 hours (mean ±sem) after m-CPP administration. This study suggests that 5-HTergic stimulation, in particular of 5-HT2 C/B receptors, play a key role both in migraine and, above all, in cluster headache mechanisms. Nitric oxide release probably is the common factor inducing head pain in both the headache forms.
AB - m-Chlorophenylpiperazine (m-CPP), a 5-HTergic agonist, is a well known migrainous headache provoking agent, probably mediated by NO release. In this study m-CPP was given to 97 subjects, including cluster headache (CH) and migraine patients, to test the hypothesis of an altered 5-HT activity/sensitivity in these pathologies. Sixty-one episodic CH patients, 44 in cluster period and 17 in remission, 10 migraine without aura sufferers, 7 low back pain (LBP) patients and 19 healthy subjects were investigated. A single oral dose of m-CPP, 0.5 mg/Kg, was given. m-CPP plasma levels were not significantly different between the 5 groups. Migrainous headache was reported by 2 healthy subjects (10.5%), 3 cluster period CH patients (6.8%), 2 CH patients in remission (11.7%), 2 migraineurs (20%) and 1 LBP patient (14.2%). Eighteen cluster period CH patients (41%) had a CH attack outside the typical hour of appearance, 2 ±0.2 hours (mean ±sem) after m-CPP administration. This study suggests that 5-HTergic stimulation, in particular of 5-HT2 C/B receptors, play a key role both in migraine and, above all, in cluster headache mechanisms. Nitric oxide release probably is the common factor inducing head pain in both the headache forms.
UR - http://www.scopus.com/inward/record.url?scp=33746349896&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746349896&partnerID=8YFLogxK
M3 - Article
VL - 18
SP - 45
JO - Italian Journal of Neurological Sciences
JF - Italian Journal of Neurological Sciences
SN - 0392-0461
IS - 4
ER -